Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HAE
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
296.43 | 363.37 | 245.44 | 223.38 |
Receivables |
207.07 | 195.71 | 216.86 | 216.07 | |
Inventory |
336.21 | 321.19 | 306.37 | 306.74 | |
Total current assets |
899.68 | 943.67 | 834.88 | 810.83 | |
Property, Plant, Equpment (Net) |
292.48 | 297.23 | 305.76 | 303.78 | |
Goodwill and Intangible Assets (Total) |
1,034.46 | 1,026.56 | 1,104.02 | 1,091.40 | |
Long Term Assets (Tax, Deferred) |
7.57 | 7.33 | 9.52 | 9.43 | |
Long-term assets (Other) |
207.97 | 216.09 | 141.74 | 149.96 | |
Total non-current assets |
1,542.47 | 1,547.22 | 1,561.05 | 1,554.57 | |
Total Assets |
2,442.16 | 2,490.89 | 2,395.93 | 2,365.40 | |
Notes Payable |
304.34 | 304.75 | 5.02 | 4.96 | |
Accounts Payable |
61.69 | 48.69 | 51.06 | 56.34 | |
Accrued Expenses |
48.27 | 52.10 | 68.19 | 38.15 | |
Other current liabilities |
134.02 | 134.33 | 158.34 | 163.80 | |
Total current liabilities |
548.32 | 539.87 | 282.60 | 263.24 | |
Long Term Debt (Total) |
920.39 | 919.99 | 1,219.57 | 1,169.20 | |
Long Term Tax Liability (Deferred) |
58.20 | 55.98 | 38.05 | 38.69 | |
Non-current Liabilities (Other) |
66.07 | 63.61 | 59.39 | 57.17 | |
Total non-current liabilities |
1,044.67 | 1,039.57 | 1,317.01 | 1,265.06 | |
Total liabilities |
1,592.98 | 1,579.44 | 1,599.61 | 1,528.30 | |
Additional Paid In Capital |
552.91 | 564.50 | 554.14 | 566.76 | |
Common Stock (Net) |
0.47 | 0.47 | 0.45 | 0.46 | |
Retained Earnings |
336.32 | 381.09 | 279.34 | 311.52 | |
Common Equity (Total) |
849.17 | 911.45 | 796.32 | 837.10 | |
Shareholders Equity (Total) |
849.17 | 911.45 | 796.32 | 837.10 | |
Shareholders Equity and Liabilities (Total) |
2,442.16 | 2,490.89 | 2,395.93 | 2,365.40 | |
Shares (Common) |
46.75 | 46.83 | 45.25 | 45.47 | |
Shareholders Equity (Tangible) |
(185.28) | (115.11) | (307.70) | (254.29) | |
Net Debt |
623.97 | 556.62 | 974.13 | 945.82 | |
Total Debt |
920.39 | 919.99 | 1,219.57 | 1,169.20 |